Affiliations: [a] Department of Psychiatry and Psychotherapy, University of Tuebingen, Tuebingen, Germany | [b] Department of Internal Medicine III-Cardiology, University of Tuebingen, Tuebingen, Germany | [c] Geriatric Center, University of Tuebingen, Tuebingen, Germany
Correspondence:
[*]
Corresponding author: Dr. Christoph Laske, Department of Psychiatry and Psychotherapy, University of Tuebingen, Osianderstr. 24, D-72076 Tuebingen, Germany. Tel.: +49 7071 2983444; Fax: +49 7071 294141; E-mail: christoph.laske@med.uni-tuebingen.de.
Abstract: Alzheimer's disease (AD) is characterized by massive neuronal cell loss in the brain. Stem cell factor (SCF) is a hematopoietic growth factor (HGF) that promotes neuroprotective effects and supports neurogenesis in the brain. In the present study, we found significantly lower SCF plasma levels in 30 early AD patients (908.5 ± 181.7 pg/ml) in comparison with 30 age-matched healthy controls (1058.3 ± 221.5 pg/ml; p = 0.006). SCF plasma levels in AD patients showed a significant inverse correlation with dementia severity as measured by ADAS-Cog (r = −0.289; p = 0.037). AD patients showed significantly lower SCF levels in cerebrospinal fluid (CSF) (131.60 ± 43.03 pg/ml) in comparison with 15 age- and gender-matched patients with other non-inflammatory neurological disease (NIND) (166.03 ± 42.5 pg/ml; p = 0.017). In addition, we found significant positive correlations between SCF and CXCL12 (also known as SDF-1) plasma levels in healthy controls (r = 0.341; p = 0.008) and between SCF and CXCL12 CSF levels in AD patients (r = 0.487; p < 0.001). In conclusion, decreased SCF plasma and CSF levels in early AD patients may contribute to a deficient hematopoietic brain support with putative pathogenic and clinical relevance. Further studies are needed to examine whether a manipulation of HGFs such as SCF could be a promising new therapeutic strategy for AD.
